India's Bharat Serum and Vaccines to Repurpose Sepsis Drug for COVID-19, an Industrial Info Market Brief
India's Bharat Serum and Vaccines to Repurpose Sepsis Drug for COVID-19, an Industrial Info Market Brief
Indian vaccine-maker Bharat Serums and Vaccines Limited (BSVL) said it has received approval from the Drug Controller General of India (DCGI) to conduct the Phase III clinical trial of Sepsis drug Ulinastatin on COVID-19 patients showing mild-to-moderate acute respiratory distress symptoms.
Ulinastatin is used in India, China and Japan in the treatment of severe sepsis and other critical clinical conditions such as acute pancreatitis. Clinical trials to evaluate efficacy of the drug are likely to commence soon in six hospitals across India, enrolling 120 patients. Results are expected to be available by December 2020.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021